NICE and Symphony Partner to Drive Digital Transformation Through Rapid Adoption of Intelligent Attended Automation

NICE and Symphony Partner to Drive Digital Transformation Through Rapid Adoption of Intelligent Attended Automation

Partnership combines NICE’s innovative attended automation and AI capabilities with Symphony’s proven methodologies for rapid integration, enabling organizations to optimize the value of RPA

HOBOKEN, N.J.–(BUSINESS WIRE)–NICE (Nasdaq: NICE) today announced that it has partnered with Symphony, a Sykes company, to expand deployment of robotic process automation, and in particular attended automation, globally. The collaboration allows organizations worldwide to benefit from NICE’s industry-first employee virtual attendant, NEVA, together with Symphony’s holistic methodologies for RPA and intelligent automation design, implementation and adoption. This partnership ensures optimal use of automation in augmenting and complementing the human workforce and drives an all-encompassing approach to intelligent automation that ultimately boosts customer experiences.

The partnership brings together the complementary capabilities of NICE and Symphony, both native to the contact center and its IT environment. NICE brings its innovative contact center solutions portfolio, including NEVA, as well as the impressive scale of its automation footprint in the contact center, spanning tens of thousands of desktops. This goes hand in hand with Symphony’s proven methodologies and vast experience in helping leading enterprises integrate automation into their organization in a way that optimizes value throughout the entire customer lifecycle, from marketing to sales to care. The partnership enables organizations to benefit from NICE’s innovative RPA capabilities, including NEVA, that boost employee engagement and performance with Symphony’s proven, holistic best practices for adoption and risk management.

Barry Cooper, President, NICE Enterprise Group, said, “This partnership between NICE and Symphony enables organizations to optimally scale their intelligent automations and expand value for customers and employees. We’re pleased to partner with Symphony to help organizations discover and then maximize the benefits of smart attended automation for their businesses.”

Richard Mitchell, Chief Technology Officer of Symphony, a SYKES company, said, “We’re proud to collaborate with NICE to bring intelligent automation solutions that enrich employee experiences and create better customer interactions. Together, we look forward to increasing the number of scaled attended automation deployments at enterprises around the world that will help drive operating efficiencies across the front, middle and back offices resulting in significant enterprise-wide value.”

About NICE

NICE (Nasdaq: NICE) is the world’s leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. NICE helps organizations of all sizes deliver better customer service, ensure compliance, combat fraud and safeguard citizens. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, are using NICE solutions. www.nice.com.

About Symphony, a SYKES company

Symphony, a SYKES company, is a professional services firm passionate about creating value for the world’s leading organizations by designing, delivering and managing digital business processes. As thought leaders, we have defined a proven methodology for strategic, at-scale deployment of Intelligent Automation (IA) solutions that drives results through digitized operations. Symphony has been named an RPA Service leader by HfS Research for four consecutive years – including being ranked #1 in Delivery of Value for 2018. For more information, visit http://www.symphonyhq.com and follow the company on LinkedIn or Twitter.

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Cooper, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Corporate Media Contact

Christopher Irwin-Dudek, 201 561 4442, ET, [email protected]

Investors

Marty Cohen, +1 551 256 5354, ET, [email protected]

Yisca Erez +972 9 775 3798, CET, [email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Software Technology Electronic Design Automation

MEDIA:

Logo
Logo

Casper Reports Third Quarter 2020 Results

Casper Reports Third Quarter 2020 Results

COVID-19 and Supply Chain Impacted Third Quarter 2020 Revenue of $123.5 million

Continued Strength in Retail Partnership Channel, up 28% YoY

Gross Margins of 55.5%, up 480 basis points YoY

NEW YORK–(BUSINESS WIRE)–
Casper Sleep Inc. (“Casper” or the “Company”) (NYSE: CSPR) today announced financial results for the quarter ended September 30, 2020 (the “third quarter 2020” or “third quarter”).

Third Quarter 2020 Financial Highlights (as compared to the quarter ended September 30, 2019)

  • Revenue decreased 3.3% to $123.5 million;
  • North America revenue increased $2.2 million or 1.8%;
  • European revenue was negligible due to the closure of our European operations in the second quarter of 2020, compared to approximately $6 million in the quarter ended September 30, 2019;
  • Direct-to-Consumer Revenue decreased 11.4% to $89.9 million;
  • Retail Partnership Revenue increased 28.3% to $33.6 million;
  • Gross Profit increased 5.9% to $68.5 million with gross margin of 55.5%, up 480 basis points;
  • Net Loss improved $7.2 million or 31.1% to $15.9 million;
  • Adjusted EBITDA loss improved by $9.3 million or 55% to $7.5 million; and
  • Cash and cash equivalents of $96.1 million at quarter end.

Philip Krim, Chief Executive Officer, comments: “Casper’s third quarter was highly productive but unfortunately we believe the results don’t fully reflect the health and potential of our business. We saw record interest for our products evidenced by record website traffic, continued to drive gross margin expansion and progress towards profitability, and had another sequential quarter of growth; however, our top-line growth was disappointing based on the initial demand signals. Challenges in our supply chain, including industry-wide shortages in textiles and chemicals critical to foam production, led to significant out-of-stock inventory both in our direct-to-consumer and retail partnership channels. Many of our core mattresses were out of stock on our website for weeks at time and we were unable to monetize the full demand from retail partners leading to cancelled orders.

We have made significant progress addressing some of our supply chain challenges. Specifically, we have on-boarded new Tier 1 and Tier 2 suppliers and vendors; we are putting in place redundancies across key supply chain points and implementing improved inventory planning; and we are actively building up our safety stock which will help protect against further disruptions. We believe the worst of our supply chain disruptions are behind us, and we are well-positioned going forward.”

Mr. Krim continued: “We are actively managing the business to best position Casper for the future and are excited about the many opportunities in front of us to enhance shareholder value as we continue to leverage our leading brand and scale our multi-channel distribution. Our organization is focused on long-term, sustainable growth and we believe our expanded distribution, current growing product offering and pipeline, strong brand awareness, refined marketing expertise and healthy balance sheet position us well to achieve our goal of sustainable Adjusted EBITDA profitability starting in mid-2021.”

Third Quarter 2020 Review (all comparisons to the three months ended September 30, 2019)

Revenue was $123.5 million, a decrease of $4.2 million, or 3.3%, compared to $127.7 million. North America revenue increased $2.2 million or 1.8%, while our European operations, which closed at the end of the second quarter of 2020, had negligible revenue compared to revenue of $6.4 million for the three months ended September 30, 2019. Direct-to-consumer sales decreased 11.4% driven by the closure of our European operations and limited store offerings in response to public health and government orders and depressed retail foot traffic due to the COVID-19 pandemic, partially offset by a modest increase in North America e-commerce sales. North America direct-to-consumer revenue decreased by $6.1 million or 6.3%. We ended the third quarter with a retail presence of 65 stores, an increase of 17 net new stores compared with our retail footprint in the third quarter of 2019, with 64 of our 65 stores open and operating as of the end of the third quarter. Total retail partnership revenue increased by $7.4 million, or 28.3%, to $33.6 million driven by growth of sales activity with existing partners and the introduction of 7 new partners compared to the same period in the prior year. We ended the quarter with 21 partners, and an expanded range of product offerings. North America retail partnership revenue increased $8.3 or 32.6%. Additionally, during the third quarter 2020, we believe our revenue was negatively impacted by supply chain constraints that extended the time required to fulfill customer orders and resulting in lost orders. We have taken active measures which we expect to mitigate these supply chain issues in future quarters.

Gross profit was $68.5 million, an increase of $3.8 million, or 5.9%, compared to $64.7 million. Gross margin of 55.5% increased 480 basis points compared to 50.7%. The increase in gross margin was primarily driven by favorable product mix related to our new mattress line launched in March 2020, as well as lower logistics costs due to a change in service provider. Gross margin also benefited from an 80 basis point partial reversal of a charge taken in the first quarter of 2020 associated with a change in logistics providers.

Sales and marketing expenses were $42.6 million, a decrease of $2.0 million, or 4.5%, compared to $44.6 million. Sales and marketing expenses decreased due to reduced advertising spend resulting from lower online and offline media costs and improved marketing efficiencies. Sales and marketing expenses as a percentage of revenue decreased 40 basis points to 34.5% from 34.9%.

General and administrative expenses, which include store operating costs, were $39.5 million, a decrease of $1.8 million, or 4.3% , compared to $41.3 million. General and administrative expenses decreased primarily due to lower payroll costs and lower operating expenses associated with our corporate workforce working from home and limited store operations, partially offset by increased expenses related to being a public company. General and administrative expenses as a percentage of revenue decreased from 32.4% to 32.0%.

The Company recorded restructuring expenses of $0.2 million related to previously announced steps to reduce our cost structure and exit our European operations.

Net loss was $15.9 million, a decrease of $7.2 million, or 31.1%, compared to a net loss of $23.0 million.

Adjusted EBITDA loss was $7.5 million, a 55% improvement of $9.3 million compared to a loss of $16.8 million. See below for a reconciliation of Adjusted EBITDA to the most directly comparable measure calculated in accordance with GAAP, net loss.

Balance Sheet

As of September 30, 2020, the Company had cash and cash equivalents of $96.1 million, compared to $67.6 million as of December 31, 2019. The increase was driven primarily by $88.0 million in net proceeds from our initial public offering, partially offset by $47.0 million of cash used in operating activities and $12.6 million invested in property and equipment, primarily to build retail stores.

Recent Initiatives

Our Casper retail stores remain critical to our multi-channel strategy, providing our customers the opportunity to experience our products before making a purchase. Since the temporary closure of all our retail stores in North America in mid-March 2020, we have reopened all of our 66 total stores as of the date of this release, with each offering walk-in shopping, private in-store appointments, curbside pick-up services, as well as virtual appointments. As part of our retail operations, we have implemented and continuously update a suite of COVID-19-related operating policies and protocols, including providing modified service offerings where advisable, with the health and safety of our customers and employees as our top priority. We have also developed procedures to enable us to responsibly and efficiently open or close our stores and adjust our service offerings as needed in response to changing COVID-19 conditions and applicable guidance from government and public health officials.

We continued to see strong demand for our products on our e-commerce platform and from our retail partners in the third quarter. COVID-19-related supply constraints and labor shortages experienced by certain of our suppliers and logistics partners, coupled with the lean levels of safety stock inventory we generally maintain as part of our flexible manufacturing model, resulted in increased delivery times for certain products on our website and impacted order fulfillment for certain of our retail partners. As a result, during the third quarter, sales in our e-commerce and retail partnership channels were meaningfully impacted by product and delivery supply chain constraints. We are actively qualifying and on-boarding new suppliers, working in close partnership with existing suppliers to re-build safety stock inventory levels, and enhancing internal inventory planning and monitoring capabilities. Taken together, we expect these actions and additional capacity to significantly mitigate inventory constraints in future quarters.

Outlook

The Company today provided an outlook for certain financial metrics for the quarter ended December 31, 2020 (the “fourth quarter 2020”), reflecting certain assumptions by management regarding the Company’s business, trends, historical seasonal factors, and the continuing impact of the COVID-19 pandemic on its business. In addition, the outlook assumes there will be no material changes in world events, weather, recent consumer trends, economic conditions, competitive landscape or other circumstances beyond our control that may adversely affect the Company’s results of operations.

In the fourth quarter 2020, the Company expects revenue of approximately $132 to $142 million, driven by year-over-year growth in the Company’s e-commerce channel and the expansion of its retail partnerships. At the mid-point, this range represents high single-digit consolidated growth and double-digit year-over-year growth for its North America business in the fourth quarter 2020.

Conference Call & Webcast Information

Casper will hold a conference call on Monday, November 16, 2020, at 8:00 a.m. Eastern time to discuss the Company’s third quarter results and other business updates. To access the conference call, interested parties may dial 866-319-1799 (for domestic callers) or 825-312-2362 (for international callers). Please call at least five minutes in advance of the start of the call to ensure that you are connected prior to the call. Interested parties may also access a live audio webcast of the call at https://ir.casper.com/news-and-events/events-and-presentations/default.aspx. Please allow 15 minutes to register. A replay of the call will be available within two hours of the conclusion of the call until January 16, 2021 at https://ir.casper.com/news-and-events/events-and-presentations/default.aspx.

Casper periodically provides information for investors on its corporate website, casper.com, and its investor relations website, ir.casper.com. This includes press releases and other information about financial performance, reports filed or furnished with the SEC and information on corporate governance.

About Casper

Casper believes everyone should sleep better. The Sleep Company has a full portfolio of obsessively engineered sleep products—including mattresses, pillows, bedding, and furniture designed in-house by the Company’s award-winning R&D team at Casper Labs. In addition to its e-commerce business, Casper owns and operates Sleep Shops across North America and its products are available at a growing list of retailers.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the impact of the COVID-19 pandemic and the related effect on our employees, customers and business operations; our expectations surrounding our ability to deliver growth, gain market share, and improve profitability; anticipated cost savings as a result of our restructuring initiatives; our planned openings and closures of our retail stores; our on-boarding of new suppliers and the effects on our inventory constraints; our future competitive position; our future results of operations and financial position including our outlook for the fourth quarter 2020; our business strategy and plans, and objectives of management for future operations and creating long-term value. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the COVID-19 pandemic could adversely impact our business, financial condition and results of operations; our ability to compete successfully in the highly competitive industries in which we operate; our ability to maintain and enhance our brand; the success of our retail store expansion plans; our ability to successfully implement our growth strategies related to launching new products; the effectiveness and efficiency of our marketing programs; our ability to manage our current operations and to manage future growth effectively; our past results may not be indicative of our future operating performance; our ability to attract new customers or retain existing customers; the growth of the market for sleep as a retail category and our ability to become a leader or maintain our leadership in the category; the impact of social media and influencers on our reputation; our ability to protect and maintain our intellectual property; our exclusive reliance on third-party contract manufacturers whose efforts we are unable to fully control; our ability to effectively implement strategic initiatives; our ability to transfer our supply chain and other business processes to a global scale; risks relating to our international operations and expansion; we are dependent on our retail partners; general economic and business conditions; we could be subject to system failures or interruptions and security breaches; risks relating to changing legal and regulatory requirements, and any failure to comply with applicable laws and regulations; we may be subject to product liability claims and other litigation; we may experience fluctuations in our quarterly operating results; we have and expect to continue to incur significant losses; risks relating to our indebtedness; our need for additional funding, which may not be available; risks relating to taxes; future sales by us our stockholders may cause the market price of our stock to decline; and risks and additional costs relating to our status as a new public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, as updated by the “Risk Factors” section of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Non-GAAP Financial Measures

Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or any other performance measure derived in accordance with GAAP.

We define Adjusted EBITDA as net loss before net interest expense, income tax expense and depreciation and amortization as further adjusted to exclude the impact of stock-based compensation expense, restructuring expenses, legal settlements, and expenses incurred in connection with our initial public offering. We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate Adjusted EBITDA in the same manner. We present Adjusted EBITDA because we consider them to be important supplemental measures of our performance and believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Management believes that investors’ understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations.

Management uses Adjusted EBITDA:

  • as a measurement of operating performance because it assists us in comparing the operating performance of our business on a consistent basis, as it removes the impact of items not directly resulting from our core operations;
  • for planning purposes, including the preparation of our internal annual operating budget and financial projections;
  • to evaluate the performance and effectiveness of our operational strategies; and
  • to evaluate our capacity to expand our business.

By providing this non-GAAP financial measure, together with the reconciliation, we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for net income or other financial statement data presented in our consolidated financial statements as indicators of financial performance. Some of the limitations are:

  • such measures do not reflect our cash expenditures;
  • such measures do not reflect changes in, or cash requirements for, our working capital needs;
  • although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future and such measures do not reflect any cash requirements for such replacements; and
  • other companies in our industry may calculate such measures differently than we do, limiting their usefulness as comparative measures.

Due to these limitations, Adjusted EBITDA should not be considered as measures of discretionary cash available to us to invest in the growth of our business. We compensate for these limitations by relying primarily on our GAAP results and using these non-GAAP measures only supplementally. As noted in the Reconciliation of Non-GAAP metrics table elsewhere in this press release, Adjusted EBITDA includes adjustments to exclude the impact of stock-based compensation expense and material infrequent items, including but not limited to the costs of our initial public offering and restructuring costs, among other items. It is reasonable to expect that these items will occur in future periods. However, we believe these adjustments are appropriate because the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our business and may complicate comparisons of our internal operating results and operating results of other companies over time. In addition, Adjusted EBITDA includes adjustments for other items that we do not expect to regularly record following our initial public offering. Each of the normal recurring adjustments and other adjustments described in this paragraph and in the Reconciliation of Non-GAAP metrics table elsewhere in this press release help management with a measure of our core operating performance over time by removing items that are not related to day-to-day operations.

Casper Sleep Inc. and Subsidiaries

Consolidated Balance Sheets

(In thousands, except per share amounts)

(Unaudited)

 

Assets

September 30, 2020

 

December 31, 2019

Current assets:

 

 

 

Cash and cash equivalents

$

96,128

 

 

$

67,578

 

Accounts receivable, net

 

17,574

 

 

 

31,059

 

Prepaid expenses and other current assets

 

14,531

 

 

 

23,924

 

Inventory, net

 

34,269

 

 

 

39,358

 

Total current assets

 

162,502

 

 

 

161,919

 

Property and equipment, net

 

67,662

 

 

 

66,262

 

Other assets

 

2,682

 

 

 

2,137

 

Total assets

$

232,846

 

 

$

230,318

 

 

 

 

 

Liabilities, Convertible Preferred Stock and Stockholders’ Equity/(Deficit)

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

26,778

 

 

 

30,734

 

Accrued expenses

 

58,246

 

 

 

73,130

 

Deferred revenue

 

10,255

 

 

 

9,673

 

Other current liabilities

 

27,073

 

 

 

34,422

 

Total current liabilities

 

122,352

 

 

 

147,959

 

Other liabilities

 

74,368

 

 

 

69,492

 

Total liabilities

 

196,720

 

 

 

217,451

 

Convertible preferred stock

 

 

 

 

319,961

 

Stockholders’ equity/(deficit):

 

 

 

Common stock

 

 

 

 

 

Additional paid-in capital

 

436,360

 

 

 

18,097

 

Accumulated other comprehensive (loss) income

 

(447

)

 

 

69

 

Accumulated deficit

 

(399,787

)

 

 

(325,260

)

Total stockholders’ equity/(deficit)

 

36,126

 

 

 

(307,094

)

Total liabilities, convertible preferred stock and stockholders’ equity

$

232,846

 

 

$

230,318

 

Casper Sleep Inc. and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

 

Three Months Ended

September 30,

Nine Months Ended

September 30,

 

 

2020

 

2019

 

2020

 

2019

Revenue

$

123,464

 

 

$

127,655

 

$

346,704

 

 

$

312,319

 

Cost of goods sold

 

54,944

 

 

 

62,942

 

 

168,155

 

 

 

157,342

 

Gross profit

 

68,520

 

 

 

64,713

 

 

178,549

 

 

 

154,977

 

Operating expenses

 

 

 

 

 

 

Sales and marketing expenses

 

42,565

 

 

 

44,551

 

 

113,220

 

 

 

113,994

 

General and administrative expense

 

39,518

 

 

 

41,311

 

 

128,522

 

 

 

105,445

 

Restructuring expenses

 

155

 

 

 

681

 

 

5,595

 

 

 

681

 

Total operating expenses

 

82,238

 

 

 

86,543

 

 

247,337

 

 

 

220,120

 

Loss from operations

 

(13,718

)

 

 

(21,830

)

 

(68,788

)

 

 

(65,143

)

Other (income) expense

 

 

 

 

 

 

Net interest expense

 

2,127

 

 

 

813

 

 

6,435

 

 

 

1,355

 

Other (income) expense, net

 

(9

)

 

 

287

 

 

(742

)

 

 

841

 

Total other expenses, net

 

2,118

 

 

 

1,100

 

 

5,693

 

 

 

2,196

 

Loss before income taxes

 

(15,836

)

 

 

(22,930

)

 

(74,481

)

 

 

(67,339

)

Income tax expense

 

20

 

 

 

93

 

 

46

 

 

 

60

 

Net loss

 

(15,856

)

 

 

(23,023

)

 

(74,527

)

 

 

(67,399

)

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

$

(0.40

)

 

$

(2.16

)

$

(2.07

)

 

$

(6.40

)

Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted

 

40,118,959

 

 

 

10,635,338

 

 

35,927,521

 

 

 

10,530,262

 

Casper Sleep Inc. and Subsidiaries

Consolidated Statement of Cash Flows

(In thousands)

(Unaudited)

 

 

Nine Months Ended

September 30,

 

 

2020

 

2019

Cash flows used in operating activities:

 

 

 

Net loss

$

(74,527

)

 

$

(67,399

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

 

11,047

 

 

 

4,804

 

Stock based compensation expense

 

9,691

 

 

 

5,648

 

Other

 

2,328

 

 

 

4,287

 

 

 

 

 

Changes in assets and liabilities:

 

 

 

Accounts receivable, net

 

13,485

 

 

 

(1,273

)

Prepaid expenses and other current assets

 

9,393

 

 

 

(16,747

)

Inventory, net

 

4,484

 

 

 

5,585

 

Other assets

 

(552

)

 

 

52

 

Accounts payable

 

(3,843

)

 

 

2,973

 

Accrued expenses

 

(14,884

)

 

 

13,263

 

Deferred revenue

 

583

 

 

 

(3,219

)

Other liabilities

 

(4,191

)

 

 

22,320

 

Net cash used in operating activities

 

(46,986

)

 

 

(29,706

)

Cash flows used in investing activities:

 

 

 

Purchases of property and equipment

 

(12,559

)

 

 

(43,631

)

Note receivable

 

 

 

 

4,000

 

Net cash used in investing activities

 

(12,559

)

 

 

(39,631

)

Cash flows provided by financing activities:

 

 

 

Exercise of stock options and warrants

 

612

 

 

 

1,318

 

Proceeds from equity issuance

 

87,999

 

 

 

68,187

 

Proceeds from borrowings

 

 

 

 

29,225

 

Repayment on borrowings

 

 

 

 

(2,922

)

Net cash provided by financing activities

 

88,611

 

 

 

95,808

 

Effect of exchange rate changes

 

(516

)

 

 

75

 

Net change in cash and cash equivalents

 

28,550

 

 

 

26,546

 

Cash and cash equivalents at beginning of period

 

67,578

 

 

 

28,355

 

Cash and cash equivalents at end of the period

$

96,128

 

 

$

54,901

 

Casper Sleep Inc. and Subsidiaries

Reconciliation of Non-GAAP Metrics

(In thousands)

(unaudited)

 

 

Three months ended

September 30,

Nine months ended

September 30,

(in thousands)

2020

 

2019

2020

 

2019

Net loss

$

(15,856

)

 

$

(23,023

)

$

(74,527

)

 

$

(67,399

)

Income tax expense

 

20

 

 

 

93

 

 

46

 

 

 

60

 

Net interest expense

 

2,127

 

 

 

813

 

 

6,435

 

 

 

1,355

 

Depreciation and amortization

 

3,313

 

 

 

2,118

 

 

9,656

 

 

 

4,804

 

Stock based compensation(a)

 

3,746

 

 

 

2,122

 

 

9,691

 

 

 

5,648

 

Restructuring(b)

 

155

 

 

 

681

 

 

5,595

 

 

 

681

 

Legal settlements(c)

 

(1,000

)

 

 

 

 

500

 

 

 

138

 

Transaction costs(d)

 

 

 

 

383

 

 

787

 

 

 

906

 

Adjusted EBITDA

$

(7,495

)

 

$

(16,813

)

$

(41,817

)

 

$

(53,807

)

(a) Represents non-cash stock-based compensation expense.

(b) Represents costs associated with strategic shifts in our business structure including exiting certain lines of business and geographies. Associated costs include severance and other employee separation costs, contract termination expenses and asset impairment.

(c) Amounts related to litigation settlements.

(d) Represents expenses incurred for professional, consulting, legal, and accounting services performed in connection with our initial public offering, which are not indicative of our ongoing costs and which were discontinued following the completion of our initial public offering.

Press Contact

[email protected]

Investor Relations Contact

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Interior Design Online Retail Retail Other Retail Home Goods Construction & Property

MEDIA:

Logo
Logo

Ares Management Becomes Largest Single Shareholder in Peach Property Group AG

Ares Management Becomes Largest Single Shareholder in Peach Property Group AG

Ares Completes Conversion of Equity Interest and Joins Board of Directors of Leading Swiss-Listed Owner and Manager of German Residential Rental Assets

LOS ANGELES & LONDON–(BUSINESS WIRE)–
Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, announced today thata fund managed by its Real Estate Group has converted a CHF 155 million (€145 million) subordinated mandatory convertible bond (“MCB”) holding in Peach Property Group AG (“Peach”) (SIX: PEAN), a Swiss owner and manager of residential rental assets with approximately 23,000 residential units located across Germany.

Ares subscribed to its investment in the MCB in early October. The MCB was part of a CHF 230 million (€213 million) capital increase that Peach sought in order to strengthen its capital base and finance the acquisition of two substantial residential portfolios. Following the conversion, Ares is now the largest single shareholder of Peach with an approximate 30% interest in the company. In conjunction with Ares’ investment, Klaus Schmitz, Managing Director in the Ares Real Estate Group, was elected as a new member to the Board of Directors of Peach.

The investment is a continuation of Ares’ long-term commitment to the German residential market, in which it has been investing since 2013. Ares originated and structured the investment, drawing upon its ability to navigate complex public transactions and leverage its expertise across its integrated investment platform.

Peach is a vertically-integrated owner and manager of German residential assets. Since 2011, Peach has acquired and managed affordable housing in Germany and to date has accumulated a portfolio valued at close to CHF 2.0 billion (€1.9 billion), consisting of high-yielding investment properties in medium-sized cities in the larger metropolitan areas of Western Germany. Peach’s services range from property acquisition to active asset management, which includes letting and sale of properties. Peach employs a differentiated customer-centric business model building on twelve physical Peach Points (tenant stores) in core locations, which allows Peach to provide superior service to its clients while at the same time driving rental growth. With its headquarters in Cologne, Peach has approximately 135 full-time employees located throughout Germany and Switzerland. Peach has been listed on the SIX Swiss Exchange since 2010.

“Peach represents an exciting opportunity to access high-yielding residential assets in Germany with an attractive risk-adjusted return profile in a market benefitting from a structural supply and demand imbalance. We believe Peach’s assets are well positioned in one of the more defensive asset classes in Europe today whilst also benefitting from what we believe is a best-in-class management team and attractive growth trajectory for the company,” said John Ruane, Partner and Co-Head of European Real Estate Equity in the Ares Real Estate Group. “With over 20,000 residential units, Peach’s customer orientated business model and digital platform makes it a stand-out player in the German residential market.”

“As the new anchor shareholder of Peach, we aim to further grow the company and drive value for all of Peach’s shareholders,” said Klaus Schmitz. “We look forward to working with the management team to support further growth of Peach over the coming years.”

About Peach Property Group AG

The Peach Property Group is a property investor focused on residential investments in Germany. The Group stands for long time experience, competence and quality. Innovative solutions for modern housing needs, strong partnerships and a wide value chain complete the profile of the Group. The portfolio consists of mainly apartment properties, typically in close reach to major metropolitan areas. In addition, the Group develops properties for its own portfolio or for the sale as condominium. The business activities of the Group cover the entire value chain, from acquisition to active asset management and the sale or letting of the properties.

Peach Property Group AG is headquartered in Zurich and has its German Group headquarters in Cologne. Peach Property Group AG is listed on the SIX Swiss Exchange (PEAN, ISIN CH0118530366). Its Board of Directors consists of Reto Garzetti (President), Peter Bodmer, Dr. Christian De Prati, Kurt Hardt and – as representative of Ares – Klaus Schmitz. For more information, see www.peachproperty.com.

About Ares Management Corporation

Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager operating integrated groups across Credit, Private Equity, Real Estate and Strategic Initiatives. Ares Management’s investment groups collaborate to deliver innovative investment solutions and consistent, attractive investment returns for fund investors throughout market cycles. As of September 30, 2020, Ares Management’s global platform had approximately $179 billion of assets under management with more than 1,400 employees operating across North America, Europe and Asia Pacific. For more information, please visit www.aresmgmt.com.

About Ares Real Estate Group

The Ares Real Estate Group manages comprehensive public and private, equity and debt strategies with approximately $14.4 billion of assets under management and approximately 80 investment professionals, as of September 30, 2020. The real estate team maintains a time-tested and consistent investment approach across equity and debt strategies focusing on major property types that have value creation opportunities, located in liquid markets with diversified economies.

Media:

Mendel Communications

Bill Mendel, 212-397-1030

[email protected]

Ares Management Corporation

Priscila Roney, 212-808-1185

[email protected]

Brittany Cash, 212-301-0347

[email protected]

Investors:

Ares Management Corporation

Carl Drake, 800-340-6597

[email protected]

KEYWORDS: California New York Switzerland United States United Kingdom North America Europe Germany

INDUSTRY KEYWORDS: Professional Services Other Professional Services Other Construction & Property Residential Building & Real Estate Finance Construction & Property Banking

MEDIA:

Logo
Logo

Trane Technologies Named to Dow Jones Sustainability North America Index for Tenth Consecutive Year

Trane Technologies Named to Dow Jones Sustainability North America Index for Tenth Consecutive Year

SWORDS, Ireland–(BUSINESS WIRE)–
Trane Technologies (NYSE:TT), a global climate innovator, has been named to the Dow Jones Sustainability North America Index (DJSI), in the capital goods sector. This is the tenth consecutive year the company has achieved this prestigious ranking, and the first as Trane Technologies.

“It’s an honor to be recognized by DJSI as a company with a longstanding commitment to sustainability and a proven history of best-in-class environmental, social and governance practices,” said Mike Lamach, chairman and chief executive officer of Trane Technologies. “Sustainability is central to our strategy, core to how we operate, and embedded in every facet of our business. Our employees around the world are aligned to one purpose – to boldly challenge what’s possible for a sustainable world. I want to thank them for all they do to help our company, our customers and our industry to create positive change.”

The Dow Jones Sustainability Indices were the first global indices to track the leading sustainability-driven public companies based on an analysis of financially material environmental, social and governance factors. The indices serve as benchmarks for investors who integrate sustainability considerations into their portfolios and provide an engagement platform for companies seeking to adopt sustainable best practices. The Dow Jones Sustainability North America Index represents the top 20% of the largest 600 North American companies in the S&P Global BMI based on long-term economic, environmental and social criteria. Trane Technologies’ inclusion for the past decade underscores the company’s commitment to incorporating sustainable practices into every aspect of its business including leading by example in its own operations, solving for customers’ climate impact with the Gigaton Challenge, and creating opportunity for all.

Boldly Challenging What’s Possible

Trane Technologies, and its leading brands Trane and Thermo King, is helping solve for some of the world’s biggest sustainability challenges and inspiring industry change with its 2030 Sustainability Commitments. These commitments include a pledge to reduce customer greenhouse gas emissions by one gigaton (2% of the world’s annual emissions), carbon-neutral operations, gender parity in leadership and a workforce reflective of the communities it serves. Trane Technologies is also making a positive difference in the community with significant investments in healthy environments for learning, access to education and workforce development.

Earlier this year, Trane Technologies debuted as a company focused on climate innovation after completing its Reverse Morse Trust transaction with Gardner Denver, now known as Ingersoll Rand.

About Trane Technologies

Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. For more on Trane Technologies, visit tranetechnologies.com.

About S&P Dow Jones Indices

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

Media Contact:

Jennifer Regina

+1-630-390-8011

[email protected]

Investors Contact:

Zachary Nagle

+1-704-990-3913

[email protected]

KEYWORDS: Europe Ireland United Kingdom

INDUSTRY KEYWORDS: Environment Logistics/Supply Chain Management Other Construction & Property Transport Construction & Property Building Systems Other Transport

MEDIA:

Logo
Logo

Avalara Announces Code-Focused Virtual Event for Developers: Avalara NEXT

Avalara Announces Code-Focused Virtual Event for Developers: Avalara NEXT

SEATTLE–(BUSINESS WIRE)–Avalara (NYSE:AVLR), a leading provider of tax compliance automation software for businesses of all sizes, today announced its first code-focused event for global tax compliance designed exclusively for developers — Avalara NEXT. The completely virtual conference will take place January 27, 2021. Bringing together developers at the forefront of global commerce and tax technology, Avalara NEXT offers digital attendees the opportunity to learn about Avalara’s new products, APIs, tools, and best practices to help developers easily build tax compliance into their business applications.

“As businesses continue to grow through digital commerce, they’re running into increased tax compliance regulations on a global scale, creating the need for a next-generation tax compliance platform to manage expanding tax obligations,” said Sanjay Parthasarathy, Chief Product Officer at Avalara. “Avalara NEXT will provide a forum for developers to connect and learn about the technology and best practices to integrate global tax compliance with their business applications.”

Avalara NEXT attendees — including Avalara customers, independent software vendors, system integrators, technology partners, and other industry experts — will walk away with an understanding of the innovation taking place at the intersection of tax compliance and commerce, and will learn about the tools and technology necessary to build tax compliance into business applications.

Avalara NEXT highlights:

  • Live coding: Watch live coding demonstrations and learn how to build a tax integration to your business application in a few hours.
  • Technical thought leaders: Hear from Avalara’s senior technical experts to learn how to optimize Avalara integrations.
  • Partner success stories: Network with technology platform partners to learn how they’ve successfully leveraged Avalara’s solutions.
  • New solutions: Learn about new global solutions from Avalara to drive value and efficiencies for your customers.

For more information or to reserve your spot for Avalara NEXT, please visit avalaranext.com.

Follow Avalara:

  • Twitter: For Avalara NEXT news and event updates, follow @Avalara and join the conversations using #AvalaraNEXT.
  • Facebook: Like Avalara on Facebook to view updates from Avalara NEXT.

About Avalara

Avalara helps businesses of all sizes get tax compliance right. In partnership with leading ERP, accounting, ecommerce, and other financial management system providers, Avalara delivers cloud-based compliance solutions for various transaction taxes, including sales and use, VAT, GST, excise, communications, lodging, and other indirect tax types. Headquartered in Seattle, Avalara has offices across the U.S. and around the world in Brazil, Europe, and India. More information at avalara.com.

Media Contact

Tommy Morgan

[email protected]

540-448-7551

Investor Contact

Jennifer Gianola

Avalara

[email protected]

650-499-9837

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Technology Finance Other Retail Accounting Professional Services Software Internet Retail Online Retail

MEDIA:

Logo
Logo

Alarm.com to Participate in Upcoming Virtual Investor Conferences

Alarm.com to Participate in Upcoming Virtual Investor Conferences

TYSONS, Va.–(BUSINESS WIRE)–
Alarm.com Holdings, Inc. (Nasdaq: ALRM), the leading platform for the intelligently connected property, today announced that Steve Valenzuela, Chief Financial Officer, will participate in and/or host one-on-one investor meetings at the following upcoming virtual investor conferences: the Credit Suisse 24th Annual Technology Conference, the Imperial Security Investor Conference, the Northland Tech Virtual Conference, the Raymond James Technology Investors Conference, and the Barclays Global Technology, Media, and Telecommunications Conference.

Event Details:

Credit Suisse 24th Annual Technology Conference

Tuesday, December 1, 2020

Hosting Investor Meetings

Imperial Security Investor Conference

Wednesday, December 2, 2020

Hosting Investor Meetings

Northland Tech Virtual Conference

Monday, December 7, 2020

Fireside Chat at 8:00 a.m. ET

Raymond James Technology Investors Conference

Tuesday, December 8, 2020

Fireside Chat at 8:50 a.m. ET

Barclays Global Technology, Media, and Telecommunications Conference

Thursday, December 10, 2020

Fireside Chat at 9:30 a.m. ET

About Alarm.com Holdings, Inc.

Alarm.com is the leading platform for the intelligently connected property. Millions of consumers and businesses depend on Alarm.com’s technology to manage and control their property from anywhere. Our platform integrates with a growing variety of Internet of Things (IoT) devices through our apps and interfaces. Our security, video, access control, intelligent automation, energy management, and wellness solutions are available through our network of thousands of professional service providers in North America and around the globe. Alarm.com’s common stock is traded on Nasdaq under the ticker symbol ALRM. For more information, please visit www.alarm.com.

Investor Relations:

David Trone

Alarm.com

[email protected]

Media Relations:

Matt Zartman

Alarm.com

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Software Technology Security

MEDIA:

Logo
Logo

BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

– Presentation featured at The Liver Meeting® 2020, the AASLD Annual Meeting, details support for the design of phage therapy candidate BX003 –

NESS ZIONA, Israel–(BUSINESS WIRE)–
BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that phages identified by BiomX with a broad host range were able to target and eradicate 89 percent of distinct gut-harbored Klebsiella pneumoniae strains isolated from samples obtained from patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). The study included over 1,000 strains isolated from over 300 patients with (IBD) or (PSC). In addition, oral administration of selected phage demonstrated efficacy in reducing target bacterial load in an in vivo model.

“These results support the potential of a phage therapy approach for the treatment of both IBD and PSC, demonstrating the ability to identify and select phage with direct relevance to patients,” commented Eran Elinav, M.D., Ph.D., Professor in the Department of Immunology at the Weizmann Institute of Science, a scientific founder of BiomX and a scientific advisor. “Our analysis of these results has informed the design and broad host range of BX003, an orally delivered candidate phage therapy targeting Klebsiella pneumoniae for the treatment of both IBD and PSC.“

The results will be featured in a poster presentation at The Liver Meeting® 2020, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) taking place Nov. 13-16, 2020.Presentation details are as follows:

Title: Broad Host Range Bacteriophage for Reduction of Klebsiella Pneumoniae as Potential Therapy in Primary Sclerosing Cholangitis (PSC) (Poster #1230)

Lead Author: Maya Kahan-Hanum, Ph.D., BiomX

Presentations will be available at the Company’s website at https://www.biomx.com/publications-2/.

About BiomX

BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, colorectal cancer, and cystic fibrosis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Additional information is available at www.biomx.com.

Safe Harbor Language

This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when this press release discusses the potential of a phage therapy approach for treatment of certain medical conditions and the ability to identify and select phage with direct relevance to patients, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, invest should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q and additional disclosures BiomX makes in its filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.

Noel Kurdi, BiomX

VP Investor Relations and Strategy

(646) 241-4400

[email protected]

Media contact:

Rich Allan, Solebury Trout

(646) 378-2958

[email protected]

KEYWORDS: United States North America Israel Middle East

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

SOTI Launches Aerospace Division

Collaboration with Ryerson University will bring together top researchers, scientists, engineers and academia to create and build the next generation of aerial drones and robotics research in Canada

MISSISSAUGA, Ontario, Nov. 16, 2020 (GLOBE NEWSWIRE) — SOTI, the world’s most trusted provider of mobility and IoT management solutions, today announced the launch of its new aerospace division, SOTI Aerospace, which will focus on advanced aerial drone and robotics research. Working with industry-leading researchers, scientists, engineers, and academia from around the world, SOTI will initially invest $20 million (USD) to fund its new aerospace division.

The new division will focus its research on vision systems for indoor environments, including self-learning, situational understanding, automatic location of people and objects, self-navigation, and smart avoidance. Initial applications will be focused on the medical sector and search & rescue operations.

As part of its commitment to innovation, SOTI is also announcing a multi-year collaboration with Ryerson University. This initiative will bring together SOTI’s top talent and Ryerson’s world-class researchers to focus on advancing aerospace research. Ryerson’s aerospace expertise will support SOTI’s research and development of aerial drone technology. SOTI will support a research chair in this field and provide real-world experience in applied aerospace technology for Ryerson students.

“SOTI Aerospace represents an exciting new era for the company and continues our commitment to invest in Canada’s technology ecosystem and work with the best and brightest minds around the world in aerial technology,” said Carl Rodrigues, President and CEO, SOTI. “Ryerson University is an ideal collaborator. Together, we aim to nurture talent and entrepreneurship, and ultimately leverage technology for good. We look forward to working together to develop aerospace innovations that enhance student education while also bringing new technology to market.”

“Ryerson University is pleased to join with SOTI to advance innovative aerospace research and technology in Canada,” said Mohamed Lachemi, Ryerson University President and Vice-Chancellor. “This collaboration unites leading aerospace researchers and industry experts, to accelerate the development of aerial drone research through dedicated funding. The agreement will also create new opportunities for our students to work on cutting-edge projects through enriched learning experiences, internships and scholarships.”

For over two decades, SOTI has been at the forefront of the mobile revolution. The new aerospace division will lean heavily on SOTI’s management team’s extensive engineering experience, as well as bring together the best and brightest from around the globe to reimagine how technology can be used to transform the world.

About SOTI

SOTI is the world’s most trusted provider of mobile and IoT management solutions, with more than 17,000 enterprise customers and millions of devices managed worldwide. SOTI’s innovative portfolio of solutions and services provide the tools organizations need to truly mobilize their operations and optimize their mobility investments. SOTI extends secure mobility management to provide an integrated solution to manage and secure all mobile devices and connected peripherals in an organization.

About Ryerson University
Ryerson University is Canada’s leader in innovative, career-oriented education. Urban, culturally diverse and inclusive, the University is home to more than 46,000 students, including 2,900 Master’s and PhD students, 3,800 faculty and staff, and over 200,000 alumni worldwide. Learn more at ryerson.ca.

For media inquiries, please contact:

SOTI Media Relations
[email protected]
1 (519) 998-1966



Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business Highlights

Participants dosed in clinical trials for lead programs in
schizophrenia, epilepsy, anxiety and Parkinson’s disease

Debuted as publicly traded entity under symbol CERE

Net proceeds of approximately $440 million raised from completed business combination transaction with ARYA Sciences Acquisition Corp II and concurrent PIPE financing

BOSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced financial results for the third quarter ended September 30, 2020 and provided recent business updates.

“During the third quarter of 2020 we made substantial progress towards our goal of becoming the premier neuroscience company,” said Tony Coles, M.D., chief executive officer and chairperson of Cerevel Therapeutics. “As a result of our business combination with Arya II and the accompanying PIPE financing, we now have the financial resources expected to fund our operating plan into 2023 and advance each of our lead programs in the clinic. Our goal is to make a profound impact in the lives of people with schizophrenia, anxiety, epilepsy and Parkinson’s disease and we have initiated enrollment in each of our clinical trials for these diseases.”


Third Quarter


and


Key Business Highlights

  • Dosed
    participants in clinical trials for all three lead programs.

°
CVL-231: the first participant was dosed in Part B of the Phase 1b trial of CVL-231 in patients with schizophrenia. The Phase 1b trial consists of Part A, a multiple ascending dose trial and Part B, a pharmacokinetic/pharmacodynamic trial. Dosing in Part A of the trial had started in the second half of 2019. Data from the Phase 1b trial are expected in the second half of 2021.
° CVL-865: the first participant was dosed in the Phase 2 REALIZE trial evaluating CVL-865 as an adjunctive therapy in adults with drug-resistant focal onset seizures. Data from the REALIZE trial are expected in the second half of 2022. Additionally, the first participant was dosed in the Phase 1 proof-of-principle trial for acute anxiety in healthy volunteers. Data from this Phase 1 trial are expected in the second half of 2021.
° Tavapadon: the first participants have been dosed in all three of the ongoing clinical trials in the Phase 3 program evaluating tavapadon in patients with Parkinson’s disease. Preliminary data readouts from the Phase 3 program are expected to be available beginning in the first half of 2023.

  • Debuted as publicly traded neuroscience company
    . On October 28, 2020, Cerevel began trading as a public company via one of the largest go-public transactions in the biopharma industry to date. Following the completion of its business combination with ARYA Sciences Acquisition Corp II (Arya II), a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors, Cerevel Therapeutics Holdings, Inc., the resulting combined company, commenced trading its shares under the symbol “CERE” and its warrants under the symbol “CEREW” on the Nasdaq Capital Market.

  • Raised net
    proceeds of approximately $440 million
    through completed business combination
    . On July 29, 2020, Cerevel Therapeutics and Arya II entered into a definitive business combination agreement. Concurrently, a group of premier healthcare investors committed to participate in the transaction through a concurrent private investment in public equity (“PIPE”) financing. On October 27, 2020, the business combination was completed and net proceeds from the transaction totaled approximately $440 million, which included funds held in Arya II’s trust account and proceeds from the PIPE financing, less transaction expenses.


Third Quarter Financial Results

  • Cash and cash equivalents: Cash and cash equivalents were $13 million as of September 30 2020. Following receipt of the net proceeds from the business combination with Arya II and the concurrent PIPE financing, Cerevel Therapeutics expects its cash and cash equivalents will be sufficient to fund its current operating plan into 2023.
  • Research and Development (R&D) Expenses: R&D expenses were $24 million for the third quarter of 2020 as compared to $17 million for the third quarter of 2019. The increase in research and development expense was primarily due to higher program costs related to advancing our pipeline and increased personnel costs as we grew our organization.
  • General and Administrative (G&A) Expenses: G&A expenses were $10 million for the third quarter of 2020 as compared to $10 million for the third quarter of 2019.
  • Net Loss: Net loss was $39 million for the third quarter of 2020, as compared to net loss of $36 million for the third quarter of 2019.

About Cerevel Therapeutics

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder. Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit www.cerevel.com.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential attributes and benefits of our product candidates, the format and timing of our product development activities and clinical trials,
including the expected timing of data announcements, and the sufficiency of our financial resources. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: that clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading “Risk Factors” in our definitive proxy statement/prospectus filed with the SEC on October 7, 2020. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:

Rachel Eides
W2O pure
[email protected]

I
nvestor Contact:

Matthew Calistri
Cerevel Therapeutics
[email protected]

TABLE 1
 
CEREVEL THERAPEUTICS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share amounts)
                       
  For the Three Months   For the Nine Months
  Ended September 30,   Ended September 30,
  2019     2020     2019     2020  
                       
Operating expenses:                      
Research and development $              17,342     $              24,026     $            28,326     $              73,168  
General and administrative 9,643     10,336     18,740     34,052  
Total operating expenses 26,985     34,362     47,066     107,220  
Loss from operations (26,985 )   (34,362 )   (47,066 )   (107,220 )
Interest income, net 368     1     1,360     210  
Other income (expense), net (8,980 )   (4,684 )   (26,423 )   (11,976 )
Loss before income taxes (35,597 )   (39,045 )   (72,129 )   (118,986 )
Income tax (provision) benefit, net     5         21  
Net loss and comprehensive loss $             (35,597 )   $             (39,040 )   $           (72,129 )   $           (118,965 )
Net loss per share, basic and diluted $                 (7.73 )   $                 (5.49 )   $             (15.66 )   $               (17.89 )
Weighted-average shares used in calculating net loss per share, basic and diluted 4,608     7,112     4,605     6,648  

TABLE 2
             
CEREVEL THERAPEUTICS HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
   
    As of     As of  
    December 31, 2019     September 30, 2020  
ASSETS            
Current assets:            
Cash and cash equivalents   $ 79,551     $ 12,808  
Prepaid expenses and other current assets   7,526     3,076  
Total current assets   87,077     15,884  
Property and equipment, net   1,476     16,620  
Operating lease assets   26,015     24,727  
Restricted cash   4,131     4,200  
Other long-term assets   2,107     5,606  
Total assets   $ 120,806     $ 67,037  
             
LIABILITIES, CONVERTIBLE STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY            
Current liabilities:            
Accounts payable   $ 2,109     $ 4,822  
Accrued expenses and other current liabilities   10,175     22,181  
Operating lease liabilities, current portion   2,592     2,206  
Total current liabilities   14,876     29,209  
Operating lease liabilities, net of current portion   25,819     29,515  
Other long-term liabilities   2,288     9,060  
Total liabilities   42,983     67,784  
Convertible stock and stockholders’ (deficit) equity   77,823     (747 )
Total liabilities, convertible stock and stockholders’ (deficit) equity   $ 120,806     $ 67,037  

TABLE 3
 
CEREVEL THERAPEUTICS HOLDINGS, INC.
SUMMARY OF CASH FLOWS
(unaudited, in thousands)
 
      For the Nine Months
      Ended September 30,
CASH FLOWS   2019     2020  
               
Net cash flows used in operating activities   $             (34,907 )   $             (76,099 )
Net cash flows used in investing activities   (550 )   (11,341 )
Net cash flows provided by financing activities   58     20,766  
Net decrease in cash, cash equivalents and restricted cash   (35,399 )   (66,674 )
Cash, cash equivalents and restricted cash, beginning of the period   95,443     83,682  
Cash, cash equivalents and restricted cash, end of the period   $              60,044     $              17,008  
               
Note:            
Cash, cash equivalents and restricted cash balances include restricted cash of $4.2 million and $4.1 million as of September 30, 2020 and December 31, 2020, respectively.  

TABLE 4
 
CEREVEL THERAPEUTICS HOLDINGS, INC.
GAAP TO NON-GAAP RECONCILIATION
(unaudited, in thousands, except per share amounts)
 
An itemized reconciliation between net loss per share on a GAAP basis and on a Non-GAAP basis is as follows:
                 
    For the Three Months   For the Nine Months
    Ended September 30,   Ended September 30,
    2019     2020     2019     2020  
                         
GAAP net loss per share, basic and diluted   $ (7.73 )   $ (5.49 )   $ (15.66 )   $ (17.89 )
Adjustments to GAAP net loss per share (as detailed below)   2.54     1.15     6.56     3.65  
Non-GAAP net loss per share, basic and diluted   $ (5.19 )   $ (4.34 )   $ (9.10 )   $ (14.24 )
Weighted-average shares used in calculating net loss per share   4,608     7,112     4,605     6,648  
                         
                         
An itemized reconciliation between net loss on a GAAP basis and on a Non-GAAP basis is as follows:
                         
    For the Three Months   For the Nine Months
    Ended September 30,   Ended September 30,
    2019     2020     2019     2020  
                         
GAAP net loss   $ (35,597 )   $ (39,040 )   $ (72,129 )   $ (118,965 )
Adjustments:                        
Research and development: equity-based compensation expense   879     1,059     1,530     2,883  
General and administrative: equity-based compensation expense   1,820     2,413     2,262     6,981  
General and administrative: write-off of deferred financing costs               2,485  
Other income (expense), net: loss (gain) on fair value remeasurement of Equity Commitment   11,880     4,650     30,202     11,300  
Other income (expense), net: loss (gain) on fair value remeasurement of Share Purchase Option   (2,900 )   30     (3,780 )   670  
Non-GAAP net loss   $ (23,918 )   $ (30,888 )   $ (41,915 )   $ (94,646 )

Use of Non-GAAP Financial Measures
We supplement our consolidated financial statements presented on the basis of U.S. generally accepted accounting principles, or GAAP, by providing additional measures which may be considered “Non-GAAP” financial measures under applicable SEC rules. Our “Non-GAAP net loss per share” and “Non-GAAP net loss” financial measures exclude the following items included in our reported, or GAAP, net loss and net loss per share financial measures: equity-based compensation expense, changes in the fair value remeasurement of our Equity Commitment and Share Purchase Option and a $2.5 million charge for the write-off of deferred financing costs associated with our IPO and other financing activities that were abandoned in June 2020 upon signing of the term sheet for our business combination agreement with ARYA Sciences Acquisition Corp II, or ARYA. We exclude equity-based compensation expense because it is a non-cash item, which is excluded from our internal operating plans and measurement of financial performance, although we consider the dilutive impact to our investors when awarding stock-based compensation and value such awards accordingly. We exclude changes in the fair value remeasurement of our Equity Commitment and Share Purchase Option because, in connection our business combination with ARYA, these instruments were terminated and the exclusion of such non-cash charges provides better period-over-period comparability of our results of operations as viewed by management. We exclude the charge for the write-off of deferred financing costs associated with our abandoned IPO and other financing activities because these were one-time, non-recurring costs and their exclusion provides better period-over-period comparability of our results of operations as viewed by management. These non-GAAP financial measures are not in accordance with GAAP in the United States and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss and net loss per share. In making any comparisons to other companies, investors should be aware that companies use different non-GAAP measures to evaluate their financial performance and should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.

TABLE 5
 
CEREVEL THERAPEUTICS HOLDINGS, INC.
GAAP TO NON-GAAP RECONCILIATION
(unaudited, in thousands, except per share amounts)
 
    For the Three Months   For the Three Months
    Ended September 30, 2019   Ended September 30, 2020  
    GAAP     Adjustments     Non-GAAP     GAAP     Adjustments     Non-GAAP  
                                     
Operating expenses:                                    
Research and development (1)   $ 17,342     $ (879 )   $ 16,463     $ 24,026     $ (1,059 )   $ 22,967  
General and administrative (2)   9,643     (1,820 )   7,823     10,336     (2,413 )   7,923  
Total operating expenses   26,985     (2,699 )   24,286     34,362     (3,472 )   30,890  
Loss from operations   (26,985 )   2,699     (24,286 )   (34,362 )   3,472     (30,890 )
Interest income, net   368         368     1         1  
Other income (expense), net (3)   (8,980 )   8,980         (4,684 )   4,680     (4 )
Loss before income taxes   (35,597 )   11,679     (23,918 )   (39,045 )   8,152     (30,893 )
Income tax (provision) benefit, net               5         5  
Net loss and comprehensive loss   $ (35,597 )   $ 11,679     $ (23,918 )   $ (39,040 )   $ 8,152     $ (30,888 )
Net loss per share, basic and diluted   $ (7.73 )   $ 2.54     $ (5.19 )   $ (5.49 )   $ 1.15     $ (4.34 )
Weighted-average shares used in calculating net loss per share, basic and diluted   4,608           4,608     7,112           7,112  
                                     
                                     
    For the Nine Months   For the Nine Months
    Ended September 30, 2019   Ended September 30, 2020
    GAAP     Adjustments     Non-GAAP     GAAP     Adjustments     Non-GAAP  
                                     
Operating expenses:                                    
Research and development (4)   $ 28,326     $ (1,530 )   $ 26,796     $ 73,168     $ (2,883 )   $ 70,285  
General and administrative (5) (6)   18,740     (2,262 )   16,478     34,052     (9,466 )   24,586  
Total operating expenses   47,066     (3,792 )   43,274     107,220     (12,349 )   94,871  
Loss from operations   (47,066 )   3,792     (43,274 )   (107,220 )   12,349     (94,871 )
Interest income, net   1,360         1,360     210         210  
Other income (expense), net (7)   (26,423 )   26,422     (1 )   (11,976 )   11,970     (6 )
Loss before income taxes   (72,129 )   30,214     (41,915 )   (118,986 )   24,319     (94,667 )
Income tax (provision) benefit, net               21         21  
Net loss and comprehensive loss   $ (72,129 )   $ 30,214     $ (41,915 )   $ (118,965 )   $ 24,319     $ (94,646 )
Net loss per share, basic and diluted   $ (15.66 )   $ 6.56     $ (9.10 )   $ (17.89 )   $ 3.65     $ (14.24 )
Weighted-average shares used in calculating net loss per share, basic and diluted   4,605           4,605     6,648           $ 6,648  

Notes For the Three Months Ended September 30, 2019 and 2020:                    
(1) GAAP Research and development expense includes $0.9 million and $1.1 million in equity-based compensation expense for the three months ended September 30, 2019 and 2020, respectively. 
(2) GAAP General and administrative expense includes $1.8 million and $2.4 million in equity-based compensation expense for the three months ended September 30, 2019 and 2020, respectively. 
(3) GAAP Other income (expense), net includes net losses of $9.0 million and $4.7 million on fair value remeasurement of our Equity Commitment and Share Purchase Option for the three months ended September 30, 2019 and 2020, respectively. 
                         
Notes For the Nine Months Ended September 30, 2019 and 2020:                    
(4) GAAP Research and development expense includes $1.5 million and $2.9 million in equity-based compensation expense for the nine months ended September 30, 2019 and 2020, respectively. 
(5) GAAP General and administrative expense includes $2.3 million and $7.0 million in equity-based compensation expense for the nine months ended September 30, 2019 and 2020, respectively. 
(6) GAAP General and administrative expense for the nine months ended September 30, 2020, includes a $2.5 million charge for the write-off of deferred financing costs associated with our IPO and other financing activities that were abandoned in June 2020, upon signing of the term sheet for our business combination agreement with ARYA Sciences Acquisition Corp II. 
(7) GAAP Other income (expense), net includes net losses of $26.4 million and $12.0 million on fair value remeasurement of our Equity Commitment and Share Purchase Option for the nine months ended September 30, 2019 and 2020, respectively. 

Use of Non-GAAP Financial Measures

We supplement our consolidated financial statements presented on the basis of U.S. generally accepted accounting principles, or GAAP, by providing additional measures which may be considered “Non-GAAP” financial measures under applicable SEC rules. Our “Non-GAAP net loss per share” and “Non-GAAP net loss” financial measures exclude the following items included in our reported, or GAAP, net loss and net loss per share financial measures: equity-based compensation expense, changes in the fair value remeasurement of our Equity Commitment and Share Purchase Option and a $2.5 million charge for the write-off of deferred financing costs associated with our IPO and other financing activities that were abandoned in June 2020 upon signing of the term sheet for our business combination agreement with ARYA Sciences Acquisition Corp II, or ARYA. We exclude equity-based compensation expense because it is a non-cash item, which is excluded from our internal operating plans and measurement of financial performance, although we consider the dilutive impact to our investors when awarding stock-based compensation and value such awards accordingly. We exclude changes in the fair value remeasurement of our Equity Commitment and Share Purchase Option because, in connection our business combination with ARYA, these instruments were terminated and the exclusion of such non-cash charges provides better period-over-period comparability of our results of operations as viewed by management. We exclude the charge for the write-off of deferred financing costs associated with our abandoned IPO and other financing activities because these were one-time, non-recurring costs and their exclusion provides better period-over-period comparability of our results of operations as viewed by management. These non-GAAP financial measures are not in accordance with GAAP in the United States and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss and net loss per share. In making any comparisons to other companies, investors should be aware that companies use different non-GAAP measures to evaluate their financial performance and should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.



PAE to Acquire Metis Solutions, Expanding and Differentiating Its Intelligence Community and National Security Portfolio

Highlights

  • PAE will acquire Metis Solutions Corporation in a $92 million all-cash transaction.
  • The acquisition further strengthens PAE’s intelligence, defense and national security businesses in areas of high priority for the U.S. federal government.
  • In conjunction with the previously announced CENTRA Technology acquisition, the combination expands and differentiates PAE’s capabilities in intelligence analysis, training and program support for intelligence and defense customers.
  • The acquisition is expected to be accretive to key financial metrics including organic revenue growth, adjusted EBITDA margins and free cash flow.
  • Metis’ business will further broaden PAE’s customer reach and adds additional attractive contract vehicles to PAE’s portfolio.

FALLS CHURCH, Va., Nov. 16, 2020 (GLOBE NEWSWIRE) — PAE (NASDAQ: PAE, PAEWW), a global leader in delivering smart solutions to the U.S. government and its allies, today announced that its subsidiary has entered into a definitive agreement to acquire Metis Solutions Corporation, a leading provider of intelligence analysis, operational and tactical training and program management, for approximately $92 million in cash. This represents a transaction multiple of approximately 9.7x CY2020 adjusted EBITDA, adjusted for estimated annual cost synergies.

PAE President and CEO John Heller commented:

“This acquisition expands and builds scale in intelligence analysis, training and program support, all of which are well-funded market areas of the U.S. government and our allied nations. Moreover, the acquisition of Metis is expected to be accretive to adjusted EBITDA margins and free cash flow. Additionally, in combination with CENTRA Technology, PAE will have significant breadth and depth across the Intelligence and National Security communities in capability and customer access.”

Metis is a leading provider of intelligence analysis, operational and tactical training and program management focused on supporting intelligence community, national security and defense customers. Headquartered in Arlington, Virginia, Metis has more than 450 employees, a majority of whom have top secret clearances with subject matter expertise across a broad range of critical national security issues.

“We are excited to join PAE and its heritage of service. Our shared cultures of service excellence and innovation make this a compelling combination. Together, we will pursue exciting new revenue opportunities,” said Christopher Wynes, Metis president and CEO. “Joining together with PAE will help accelerate growth in our intelligence and national security business and enable us to pursue a broader customer base across more markets.”

Strategic and Financial Benefits of the Acquisition

  • Breadth of Contract Vehicles
    : The transaction brings more than eight strategic indefinite delivery, indefinite quantity contract vehicles, representing more than $60 billion of ceiling value that is expected to improve PAE’s business development pipeline in terms of number, size and win-rate percentage of opportunities.
  • Broadens Offerings
    and Capabilities
    : Expands and builds scale in PAE’s intelligence analysis, training and program support business areas. These market areas are all well-funded by the U.S. government and our allied nations.
  • Expands
    Whitespace Opportunity
    : Strategically positions PAE with new customers across the intelligence and defense communities.
  • Attractive Financial Profile
    :
     Metis’ current financial profile, coupled with expected cost synergies, is expected to be accretive to organic revenue growth, adjusted EBITDA margins and free cash flow per share.

Financing and Approvals

The transaction has been unanimously approved by the boards of directors of both PAE and Metis. It is expected to close this quarter. PAE expects to fund the purchase price of approximately $92 million with cash on hand and utilization of its delayed draw term loan.

PAE is reiterating its fiscal year 2020 financial outlook provided on November 5th, 2020. The 2020 financial outlook does not incorporate anticipated financial results of CENTRA or Metis.

Advisors

Crowell & Moring LLP acted as legal advisor to PAE in connection with the transaction.

Miles & Stockbridge P.C. acted as legal advisor and Raymond James & Associates, Inc. acted as financial advisor to Metis in connection with the transaction.

Conference Call and Webcast

PAE will host a conference call and webcast, November 16, 2020, at 8 a.m. ET and will post an investor presentation to its website. Management will review details of the acquisition, followed by a question-and-answer session. Listeners and other interested parties will be able to access a presentation summarizing the transaction on the PAE Investor Relations website.

Interested parties are invited to join the webcast from the PAE Investor Relations website. Due to the COVID-19 pandemic, teleconference providers globally are experiencing significant increases in conference call volume. As such, PAE recommends that parties participate by joining the webcast. Alternatively, if the webcast is not practical, attendees may listen to the conference call by dialing (855) 982-6676 and entering conference ID 2168537. The international dial-in access number is (614) 999-9188.

PAE will post an archive of the webcast following the call on the PAE Investor Relations website.

About PAE

For 65 years, PAE has tackled the world’s toughest challenges to deliver agile and steadfast solutions to the U.S. government and its allies. With a global workforce of approximately 20,000 on all seven continents and in approximately 60 countries, PAE delivers a broad range of operational support services to meet the critical needs of our clients. Our headquarters is in Falls Church, Virginia. Find us online at pae.com, on Facebook, Twitter and LinkedIn.

Forward-Looking Statements

This press release contains a number of “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our expectations and projections regarding the acquisition of Metis Solutions Corporation, PAE’s possible or assumed future results of operations, financial results, backlog, estimation of resources for contracts, strategy for and management of growth, needs for additional capital, risks related to government contracting generally, including failures to properly manage projects and subcontractors, susceptibility to claims, litigation and other disputes, and risks related to public health crises. These forward-looking statements are based on PAE’s management’s current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside PAE’s management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

Forward-looking statements included in this release speak only as of the date of this release. PAE does not undertake any obligation to update its forward-looking statements to reflect events or circumstances after the date of this release except as may be required by the federal securities laws.

Non-GAAP Financial Measures

PAE Incorporated (the “Company”) uses adjusted EBITDA, adjusted EBITDA margin and free cash flow as supplemental non-GAAP measures of performance. PAE defines EBITDA as net income excluding (i) interest expense, (ii) provision for or benefit from income taxes and (iii) depreciation and amortization. Adjusted EBITDA excludes certain amounts included in EBITDA. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by revenues expressed as a percentage. Free cash flow is defined as cash flow provided by operating activities less capital expenditures.

PAE believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating the acquisition by PAE of Metis Solutions Corporation and the projected future operating and financial results of PAE. The non-GAAP financial measures provided in this press release are forward-looking.

PAE is not providing a quantitative reconciliation of adjusted EBITDA or adjusted EBITDA margin in reliance on the “unreasonable efforts” exception for forward-looking non-GAAP measures set forth in SEC rules because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated without unreasonable effort and expense. In this regard, the Company does not provide a reconciliation of forward-looking adjusted EBITDA (non-GAAP) to GAAP net income, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate projected net income may vary significantly based on actual events, the Company is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income at this time. The amounts of these deductions may be material and, therefore, could result in projected GAAP net income being materially less than is indicated by estimated adjusted EBITDA (non-GAAP). In addition, the Company does not provide a reconciliation of forward-looking free cash flow (non-GAAP) to GAAP cash flows provided by operating activities and GAAP cash used in investing activities, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain line items used to calculate projected cash flows provided by operating activities and cash used in investing activities may vary significantly based on actual events, the Company is not able to forecast on a GAAP basis with reasonable certainty all line items needed in order to provide a GAAP calculation of projected free cash flow at this time.

Use of Projections

This press release contains projections with respect to the Company and Metis Solutions Corporation. The Company’s independent auditors have not audited, reviewed, compiled, or performed any procedures with respect to the projections for the purpose of their inclusion in this press release, and accordingly, did not express an opinion or provide any other form of assurance with respect thereto for the purpose of this press release. These projections should not be relied upon as being necessarily indicative of future results.

For investor inquiries regarding PAE:

Mark Zindler
Vice President Investor Relations
PAE
703-717-6017
[email protected]

For media inquiries regarding PAE:

Terrence Nowlin
Senior Communications Manager
PAE
703-656-7423
[email protected]